基于树突状细胞的免疫疗法及其在结直肠癌免疫治疗中的潜在应用。
Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy.
作者信息
Aldahlawi Alia M, Abdullah Samaa Taha
机构信息
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Immunology Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
出版信息
J Microsc Ultrastruct. 2021 Jul 9;10(3):107-113. doi: 10.4103/jmau.jmau_20_21. eCollection 2022 Jul-Sep.
Dendritic cells (DCs) are professional antigen-presenting cells, which are resident or proliferating in organs. Major histocompatibility complex (MHC) Class I and II on DCs in normal steady conditions process and present antigens including cancer antigens. Many approaches are used to enhance antigen presentation process of DCs and capture cancer cells. DCs are harvested from cancer patients and manipulated in DC-based cancer immunotherapy. In addition, DCs' vaccines and other anticancer therapy combinations were discussed to optimize DCs' efficiency for cancer immunotherapy. This review addressed the use of the human conventional type-1 DCs, OX40 plasmacytoid DCs, and DCs-derived exosomes. In addition, different combinations with DCs therapy such as combination with the monoclonal antibody, cytokine-induced killer cells, adjuvants, chemotherapy (DCs-based chemoimmunotherapy), and nanoparticles were listed and explored for their effectiveness against cancer, and mainly against colorectal cancer.
树突状细胞（DCs）是专职抗原呈递细胞，存在于或增殖于器官中。在正常稳态条件下，DCs上的主要组织相容性复合体（MHC）I类和II类分子处理并呈递包括癌症抗原在内的抗原。人们采用了多种方法来增强DCs的抗原呈递过程并捕获癌细胞。在基于DCs的癌症免疫治疗中，从癌症患者体内采集DCs并进行处理。此外，还讨论了DCs疫苗及其他抗癌治疗组合，以优化DCs在癌症免疫治疗中的效率。本综述探讨了人类传统1型DCs、OX40浆细胞样DCs以及DCs衍生的外泌体的应用。此外，还列出并探讨了DCs治疗的不同组合，如与单克隆抗体、细胞因子诱导的杀伤细胞、佐剂、化疗（基于DCs的化学免疫疗法）和纳米颗粒的组合，以及它们对癌症尤其是结直肠癌的疗效。
Zotero 插件